Shares of Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) have earned an average recommendation of “Buy” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and four have given a strong buy recommendation to the company.
GLX has been the subject of a number of research analyst reports. Citigroup raised shares of Bradmer Pharmaceuticals to a “hold” rating in a research note on Tuesday, February 24th. ATB Cormark Capital Markets downgraded shares of Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a report on Thursday, February 5th. Finally, Chardan Capital upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, May 4th.
Read Our Latest Research Report on GLX
Bradmer Pharmaceuticals Price Performance
Further Reading
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
